Lyme disease is the most common vector-borne illness in the Northern Hemisphere1,2. It is caused by Borrelia bacteria transmitted to humans by infected Ixodes ticks3. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 300,000 Americans are diagnosed with Lyme disease each year with at least a further 200,000 cases in Europe1,2.
- Valneva and Pfizer announced a collaboration to develop and commercialize VLA15 in April 2020.4
- VLA15 is currently the only active vaccine program in clinical development against Lyme disease.
- VLA15 is in Phase 2 clinical development5 and interim Phase 2 data are expected in 2020.
- The VLA15 program was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in July 2017.6
- VLA15 is a multivalent, protein subunit vaccine that targets the outer surface protein A (OspA) of Borrelia, an established mechanism of action for Lyme disease vaccine. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.
Additional information about Lyme disease:
- How many people get Lyme disease? | Lyme Disease | CDC. (n.d.). Retrieved from https://www.cdc.gov/lyme/stats/humancases.html
- Estimated from available national data. Number largely underestimated based on WHO Europe Lyme Report as case reporting is highly inconsistent in Europe and many LB infections go undiagnosed; ECDC tick-borne-diseases- meeting-report
- Stanek et al. 2012, The Lancet 379:461–473
- Valneva press release: Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15
- Valneva press release: Valneva Initiates Phase 2 Clinical Development For Its Lyme Disease Vaccine Candidate
- Valneva press release: Valneva Receives FDA Fast Track Designation for its Lyme Disease Vaccine Candidate VLA15